IDH2 and acute myeloid leukemia: Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes and assessment outcomes in the largest relapsed or refractory mutant-IDH2 AML patient shows a 40.3% overall response rate with 9.3 months median overall survival, and 19.7 months overall survival for those who attained complete remission (Stein et al., 2017).